title: [The expression of APE1 and its correlation with prognostic significance after 252Cf radiotherapy in cervical cancer].
abstract: OBJECTIVE
  To investigate the expression feature of the apurinic/apyrimidinic endonuclease (APE1) and its correlation with clinicopathology and prognostic significance after 252Cf radiotherapy in cervical cancer.
  
  
  METHODS
  The expression of APE1 was detected by immunohistochemistry technique in 89 cases of cervical cancer (treated by 252Cf), 15 cases cervical intraepithelial neoplasia (CIN) and 10 cases of normal cervical tissue, and its association with clinicopathological data as well as prognosis were analyzed.
  
  
  RESULTS
  The expression of APE1 in cervical cancer is higher significantly than that in normal cervical tissue and CIN (P < 0.01). In normal cervical tissue and CIN, the APE1 express was located in the nucleus. In cervical cancer, the APE1 express was located in the nucleus (59), cytoplasm (8) or nucleus and cytoplasm (22), the location of APE1 was related with FIGO stage and pathological grade (P < 0.01), and not related with lymph node metastasis. The level of APE1 express related with FIGO stage, pathological grade and lymph node metastasis (P < 0.05), and not related with age and pathological type. The Kaplan-Meier survival analysis demonstrated that the survival time of the group of APE1 nucleus expression (median survival time is 70.9 months) and the group of APE1 low expression (median survival time is 75.8 months) is longer significantly than that of the group of APE1 cytoplasm expression (median survival time is 57.8 months) and the group of APE1 high expression (median survival time is 56.5 months) (P = 0.025, 0.001).
  
  
  CONCLUSIONS
  The dystopic express of APE1 might play a pivotal role in carcinogenesis and progression of cervical cancer, and the express of APE1 might estimate the prognosis after 252Cf radiotherapy.
authors.affiliation: Center of Cancer, Daping Hospital, Third Military Medical University, Chongqing 400042, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Qing
authors.forename: Dong
authors.initials: D
authors.lastname: Wang
authors.forename: Xin
authors.initials: X
authors.lastname: Lei
authors.forename: De-Bing
authors.initials: DB
authors.lastname: Xiang
authors.forename: Meng-Xia
authors.initials: MX
authors.lastname: Li
authors.forename: Zeng-Peng
authors.initials: ZP
authors.lastname: Li
authors.forename: Jin-Lu
authors.initials: JL
authors.lastname: Shan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002142:Californium / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000532:radiotherapy*; D043603:DNA-(Apurinic or Apyrimidinic Site) Lyase / Q000235:genetics / Q000378:metabolism*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009502:Neutrons; D011379:Prognosis; D002583:Uterine Cervical Neoplasms / Q000378:metabolism* / Q000532:radiotherapy*
chemical_list: D002142:Californium; C085108:APEX1 protein, human; D043603:DNA-(Apurinic or Apyrimidinic Site) Lyase